<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flurandrenolide (Fludroxycortide): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flurandrenolide (Fludroxycortide): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flurandrenolide (Fludroxycortide): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8468" href="/d/html/8468.html" rel="external">see "Flurandrenolide (Fludroxycortide): Drug information"</a> and <a class="drug drug_patient" data-topicid="12488" href="/d/html/12488.html" rel="external">see "Flurandrenolide (Fludroxycortide): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F173009"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cordran;</li>
<li>Nolix [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1014735"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F173014"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid hypothalamic-pituitary-adrenal axis suppression. If no improvement is seen within 2 weeks of therapy initiation, reassessment of diagnosis may be necessary. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db00c349-e8c7-4629-a65f-c9656671bb40">Dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatoses (steroid-responsive, including contact/atopic dermatitis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Topical:</p>
<p style="text-indent:-2em;margin-left:6em;">Cream, lotion, ointment: Apply small quantity or thin film 2 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Tape: Apply 1 to 2 times daily; particularly useful on dry, scaling localized lesions.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112125"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112126"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F173011"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8468" href="/d/html/8468.html" rel="external">see "Flurandrenolide (Fludroxycortide): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b>
<b>Topical: Note:</b> Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, lotion, ointment: Apply thin film to affected area 2 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Tape: Apply 1 to 2 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991132"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988464"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F172990"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Burning sensation</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Acne vulgaris, acneiform eruptions, allergic contact dermatitis, atrophic striae, folliculitis, hypopigmentation, hypertrichosis, maceration of the skin, miliaria, perioral dermatitis, pruritus, skin atrophy, xeroderma</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Secondary infection</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Local irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Hypersensitivity, skin discoloration</p></div>
<div class="block coi drugH1Div" id="F173002"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to flurandrenolide or any component of the formulation; lesions exuding serum or in intertriginous areas (tape)</p></div>
<div class="block war drugH1Div" id="F172987"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Patients receiving large doses of potent topical steroids should be periodically evaluated for HPA axis suppression using urinary free cortisol and ACTH stimulation tests. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully by reducing the frequency of application or substitution of a less potent steroid. Recovery is usually prompt and complete upon drug discontinuation, but may require supplemental systemic corticosteroids if signs and symptoms of steroid withdrawal occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Allergic contact dermatitis can occur and it is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue if dermatological infection persists despite appropriate antimicrobial therapy (Del Ross, 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; discontinue flurandrenolide treatment if infection does not resolve promptly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tape: Most effective for dry, scaling, localized lesions</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area (including diaper area). Avoid use with occlusive dressing (including tight-fitting diapers or plastic pants) unless directed by a health care provider. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878465"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F172996"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cordran: 0.025% (120 g [DSC]); 0.05% (120 g) [contains cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nolix: 0.05% (60 g [DSC]) [contains cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (60 g [DSC], 120 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cordran: 0.05% (120 mL) [contains benzyl alcohol, cetyl alcohol, menthol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nolix: 0.05% (120 mL [DSC]) [contains benzyl alcohol, cetyl alcohol, menthol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cordran: 0.05% (60 g [DSC]) [contains cetyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (60 g [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tape, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cordran: 4 mcg/cm<sup>2</sup> (1 ea)</p></div>
<div class="block geq drugH1Div" id="F172983"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F173003"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Cordran External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $12.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Flurandrenolide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $8.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Cordran External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $12.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Flurandrenolide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $3.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tape</b> (Cordran External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mcg/cm<sup>2</sup> (per each): $982.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53566762"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Cream, lotion, ointment, tape: Intermediate potency corticosteroid </p></div>
<div class="block admp drugH1Div" id="F52612870"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical:</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, lotion, ointment: For external use only. Apply a thin film to clean, dry skin and rub in gently. Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area. Use of occlusive dressings is not recommended unless directed by the health care provider. Do not use tight-fitting diapers or plastic pants on infants and children being treated in the diaper area. Shake lotion well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Tape: For external use only. Apply to clean, dry skin (allow skin to dry 1 hour before applying new tape). Remove scales, crusts, dried exudates, and previously used ointments or creams from areas to be covered. Shave or clip hair in the treatment area to promote adherence and easy removal. If a shower or bath is to be taken, it should be completed before the tape is applied and the skin should be dry prior to application of the tape. Do not tear tape; always cut. Use of occlusive dressings (including tight-fitting diapers or plastic pants) is not recommended unless used for management of psoriasis or recalcitrant conditions. Replacement of tape every 12 hours is best tolerated, but tape may be left in place for 24 hours if it is well tolerated and adheres satisfactorily. May be used just at night and removed during the day.</p></div>
<div class="block adm drugH1Div" id="F172999"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Cream, lotion, ointment: For external use only. Apply a thin film to clean, dry skin and rub in gently. Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area. Use of occlusive dressings is not recommended unless directed by a healthcare provider. Shake lotion well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Tape: Apply to clean, dry skin (allow skin to dry 1 hour before applying new tape). Remove scales, crusts, dried exudates, and previously used ointments or creams from areas to be covered, use a germicidal soap or cleanser to prevent the development of odor under the tape. Shave or clip hair in the treatment area to promote adherence and easy removal. If a shower or bath is to be taken, it should be completed before the tape is applied and the skin should be dry prior to application of the tape. Keep skin smooth and press into place. Do not tear tape; always cut. If tape ends loosen prematurely, they may be cut off and replaced with fresh tape. Use of occlusive dressings (including tight-fitting diapers or plastic pants) is not recommended unless used for management of psoriasis or recalcitrant conditions. Replacement of tape every 12 hours is best tolerated, but may be left in place for 24 hours if well tolerated. If necessary, may be used just at night and removed during the day.</p></div>
<div class="block sts drugH1Div" id="F15666307"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Cream, lotion, ointment: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from light.  Protect lotion from freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Tape: Store at 20°C to 25°C (68°F to 77°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53566969"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block mst drugH1Div" id="F173023"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cordran may be confused with Cardura, codeine, Cordarone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299356"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F172992"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56233680"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis, in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F13277396"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic bioavailability of topical corticosteroids is variable (eg, integrity of skin, use of occlusion) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, arm pit, skin folds, vulva) (Chi 2017), and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block mopp drugH1Div" id="F53566958"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth in pediatric patients; assess hypothalamic-pituitary-adrenal axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary-free cortisol test).</p></div>
<div class="block pha drugH1Div" id="F172986"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.  Flurandrenolide has intermediate range potency.</p></div>
<div class="block phk drugH1Div" id="F173001"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Adequate with intact skin; repeated applications lead to depot effects on skin, potentially resulting in enhanced percutaneous absorption. Absorption increased in inflamed skin or use of occlusive dressings.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine; feces (small amounts)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F173004"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Drenison</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Haelan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Haelan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Drenison</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Drenison</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cordran | Flurandrenolide | Nolix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Drenison</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol</i>. 2021;157(7):788-795. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-10. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol</i> Venereol. 2017;31(5):761-773. doi:10.1111/jdv.14101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy.<i> Cochrane Database Syst Rev</i>. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cordran Cream and Ointment (flurandrenolide) [prescribing information]. Exton, PA: Aqua Pharmaceuticals; May 2017.</div>
</li>
<li>
<div class="reference">
                  Cordran Tape (flurandrenolide) [prescribing information]. Exton, PA: Almirall, LLC; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” <i>J Natl Cancer Inst</i>, 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nolix (flurandrenolide) lotion [prescribing information]. Philadelphia, PA: Medical Products Laboratories; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol</i>. 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician</i>. 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol</i>. 2009;8(12):1093-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period.<i> J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flurandrenolide-fludroxycortide-pediatric-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 96760 Version 146.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
